Title: Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.
Abstract: When used as monotherapy or in conjunction with metformin (Glucophage) or thiazolidinediones, the DPP-4 inhibitor sitagliptin (Januvia) decreases A1C levels by 0.7 percent, but there are no data on patient-oriented outcomes or long-term safety. Until more studies are completed, it should only be used in individual patients when there are reasons that other better-studied agents are not sufficient.
Publication Year: 2009
Publication Date: 2009-03-01
Language: en
Type: article
Indexed In: ['pubmed']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot